HDAC6 as privileged target in drug discovery: A perspective

S Pulya, SA Amin, N Adhikari, S Biswas, T Jha… - Pharmacological …, 2021 - Elsevier
Abstract HDAC6, a class IIB HDAC isoenzyme, stands unique in its structural and
physiological functions. Besides histone modification, largely due to its cytoplasmic …

[HTML][HTML] Charcot-Marie-Tooth: from molecules to therapy

J Morena, A Gupta, JC Hoyle - International journal of molecular sciences, 2019 - mdpi.com
Charcot-Marie-Tooth (CMT) is the most prevalent category of inherited neuropathy. The most
common inheritance pattern is autosomal dominant, though there also are X-linked and …

Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target

S Lechner, MIP Malgapo, C Grätz… - Nature chemical …, 2022 - nature.com
Drugs that target histone deacetylase (HDAC) entered the pharmacopoeia in the 2000s.
However, some enigmatic phenotypes suggest off-target engagement. Here, we developed …

A review of progress in histone deacetylase 6 inhibitors research: structural specificity and functional diversity

XH Zhang, Qin-Ma, HP Wu, MY Khamis… - Journal of medicinal …, 2021 - ACS Publications
Histone deacetylases (HDACs) are essential for maintaining homeostasis by catalyzing
histone deacetylation. Aberrant expression of HDACs is associated with various human …

New developments in Charcot–Marie–Tooth neuropathy and related diseases

D Pareyson, P Saveri, C Pisciotta - Current opinion in neurology, 2017 - journals.lww.com
This is a rapidly evolving field where better understanding of pathophysiology is paving the
way to develop potentially effective treatments, part of which will soon be tested in patients …

[HTML][HTML] HDAC6 in Diseases of Cognition and of Neurons

P LoPresti - Cells, 2020 - mdpi.com
Central nervous system (CNS) neurodegenerative diseases are characterized by faulty
intracellular transport, cognition, and aggregate regulation. Traditionally, neuroprotection …

Old but gold: tracking the new guise of histone deacetylase 6 (HDAC6) enzyme as a biomarker and therapeutic target in rare diseases

M Brindisi, AP Saraswati, S Brogi… - Journal of medicinal …, 2019 - ACS Publications
Epigenetic regulation orchestrates many cellular processes and greatly influences key
disease mechanisms. Histone deacetylase (HDAC) enzymes play a crucial role either as …

Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010–2020)

Y Li, S Sang, W Ren, Y Pei, Y Bian, Y Chen… - European Journal of …, 2021 - Elsevier
Alzheimer's disease (AD) is one of the most common neurodegenerative disorders, which is
characterized by the primary risk factor, age. Several attempts have been made to treat AD …

[PDF][PDF] Human motor units in microfluidic devices are impaired by FUS mutations and improved by HDAC6 inhibition

KS Dittlau, EN Krasnow, L Fumagalli, T Vandoorne… - Stem Cell Reports, 2021 - cell.com
Neuromuscular junctions (NMJs) ensure communication between motor neurons (MNs) and
muscle; however, in MN disorders, such as amyotrophic lateral sclerosis (ALS), NMJs …

HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease

V Benoy, L Van Helleputte, R Prior, C d'Ydewalle… - Brain, 2018 - academic.oup.com
Peripheral nerve axons require a well-organized axonal microtubule network for efficient
transport to ensure the constant crosstalk between soma and synapse. Mutations in more …